Original Article

You have full text access to this OnlineOpen article

Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers

Yoshifumi Baba MD^1,†,
Katsuhiko Nosho MD^1,†,
Kaori Shima PhD^1,†,
Marika Hayashi BS¹,
Jeffrey A. Meyerhardt MD¹,
Andrew T. Chan MD²,
Edward Giovannucci MD^3,4,
Charles S. Fuchs MD^1,4,
Shuji Ogino MD^1,5,‡,*

Article first published online: 8 NOV 2010

DOI: 10.1002/cncr.25630

Issue

Cancer

Volume 117, Issue 7, pages 1399–1408, 1 April 2011

Additional Information

How to Cite

Baba, Y., Nosho, K., Shima, K., Hayashi, M., Meyerhardt, J. A., Chan, A. T., Giovannucci, E., Fuchs, C. S. and Ogino, S. (2011), Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer, 117: 1399–1408. doi: 10.1002/cncr.25630

Author Information

¹
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts
²
Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts
³
Department of Epidemiology and Nutrition, Harvard School of Public Health, Boston, Massachusetts
⁴
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
⁵
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

^†
Y.B., K.N., and K.S. contributed equally.
^‡
Fax: (617) 277-9015

Email: Shuji Ogino MD (shuji_ogino@dfci.harvard.edu)

^*Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, 44 Binney St., Room JF-215C, Boston, MA 02115

Publication History

Issue published online: 18 MAR 2011
Article first published online: 8 NOV 2010
Manuscript Accepted: 3 AUG 2010
Manuscript Revised: 28 JUL 2010
Manuscript Received: 1 JUL 2010

ARTICLE TOOLS

View Full Article (HTML) Get PDF (357K)

REFERENCES

1
Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9: 550-562.
2
Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129: 1261-1274.
3
Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008; 27: 6473-6488.
4
Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010; 28: 1075-1083.
5
Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009; 59: 111-137.
Direct Link:
6
Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest. 2008; 118: 3003-3006.
7
Li R, Dai H, Wheeler TM, et al. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology. Clin Cancer Res. 2009; 15: 3568-3573.
8
Tomita Y, Morooka T, Hoshida Y, et al. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res. 2006; 12: 3070-3077.
9
Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005; 23: 1473-1482.
10
Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer. Inst 2004; 96: 1133-1141.
11
Nam SY, Lee HS, Jung GA, et al. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. Apmis. 2003; 111: 1105-1113.
Direct Link:
12
Shah A, Swain WA, Richardson D, et al. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer. Res 2005; 11: 2930-2936.
13
Javle MM, Yu J, Khoury T, et al. Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol. 2006; 21: 1744-1751.
Direct Link:
14
Chadha KS, Khoury T, Yu J, et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 2006; 13: 933-939.
15
Lugli A, Zlobec I, Minoo P, et al. Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal-regulated kinase, and phosphorylated AKT in colorectal cancer-a tissue microarray-based approach. Hum Pathol. 2006; 37: 1022-1031.
16
Kato S, Iida S, Higuchi T, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer. 2007; 121: 1771-1778.
Direct Link:
17
Schmitz KJ, Wohlschlaeger J, Alakus H, et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch. 2007; 450: 151-159.
18
Colakoglu T, Yildirim S, Kayaselcuk F, et al. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Am J Surg. 2008; 195: 719-725.
19
Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008; 10: 13-27.
20
Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007; 7: 763-777.
21
Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008; 26: 5713-5720.
22
Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007; 356: 2131-2142.
23
Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005; 7: 413-421.
24
Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006; 8: 582-588.
25
Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008; 10: 534-541.
26
Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006; 19: 59-68.
27
Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006; 8: 209-217.
28
Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006; 55: 1000-1006.
29
Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38: 787-793.
30
Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008; 3: e3698.
31
Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007; 9: 305-314.
32
Ogino S, Kawasaki T, Nosho K, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer. 2008; 122: 2767-2773.
Direct Link:
33
Irahara N, Nosho K, Baba Y, et al. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn. 2010; 12: 177-183.
34
Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers. 2008; 23: 1-9.
35
Horst D, Reu S, Kriegl L, Engel J, Kirchner T, Jung A. The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer. Cancer. 2009; 115: 2063-2070.
Direct Link:
36
Zlobec I, Minoo P, Baumhoer D, et al. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer. 2008; 112: 495-502.
Direct Link:
37
Buergy D, Fuchs T, Kambakamba P, et al. Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer. Cancer. 2009; 115: 4667-4678.
Direct Link:
38
Watanabe T, Kobunai T, Sakamoto E, et al. Gene expression signature for recurrence in stage III colorectal cancers. Cancer. 2009; 115: 283-292.
Direct Link:
39
Vilkin A, Niv Y, Nagasaka T, et al. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. Cancer. 2009; 115: 760-769.
Direct Link:
40
Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer. 2002; 94: 3127-3134.
Direct Link:
41
Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer--the present. Histopathology. 2008; 52: 82-90.
Direct Link:
42
Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23: 609-618.
43
Fanelli D. Do pressures to publish increase scientists' bias? An empirical support from US States Data. PLoS One. 2010; 5: e10271.
44
Wyszomierski SL, Yu D. A knotty turnabout?: Akt1 as a metastasis suppressor. Cancer Cell. 2005; 8: 437-439.
45
Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell. 2005; 20: 539-550.
46
Liu H, Radisky DC, Nelson CM, et al. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A. 2006; 103: 4134-4139.
47
Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 2004; 64: 3171-3178.
48
Kodama Y, Baxter RC, Martin JL. Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line. Am J Respir Cell Mol Biol. 2002; 27: 336-344.
49
Irie HY, Pearline RV, Grueneberg D, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol. 2005; 171: 1023-1034.
50
Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005; 7: 561-573.

View Full Article (HTML) Get PDF (357K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers

Cancer

How to Cite

Author Information

Publication History

ARTICLE TOOLS

REFERENCES

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers

Cancer

How to Cite

Author Information

Publication History

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

REFERENCES

More content like this